Cyclophosphamide

• UNSPSC Description:

  Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic activity, a immunosuppressant.

• Target Antigen:

  DNA Alkylator/Crosslinker

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Cyclophosphamide.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : 33.33 mg/mL (ultrasonic)

• Smiles:

  ClCCN(CCCl)P1(OCCCN1)=O

• Molecular Weight:

  261.089

• References & Citations:

  [1]Schwartz PS, et al. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001 Dec;60(6):1268-1279.|[2]al-Jafari AA, et al. Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology. 1995 Jan 19;96(1):1-6.|[3]Harris RN, et al. Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokineticstudy. Cancer Chemother Pharmacol. 1984;12(3):167-72.|[4]Liu P, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010 Jan;33(1):53-9.|[5]Dominique A Ramirez, et al. Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics. Drug Metab Dispos. 2019, 47, 3.|[6]H. Roness, et al. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. J Assist Reprod Genet. 2019, 36, 9.|[7]Susana Salva, et al. Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice. Int Immunopharmacol. 2014, 22, 1.ACS Appl Bio Mater. 2023 Sep 29.|Biochem Pharmacol. 2021 Jan;183:114340.|Biomed Res Int. 13 Jul 2022.|bioRxiv. 2023 Feb 27.|Breast Cancer Res Treat. 2023 May 19.|Cell Death Dis. 2020 Nov 12;11(11):976.|Cell Rep Med. 2024 Nov 25:101837.|Eur J Pharm Sci. 2024 Jul 21:106860.|Evid Based Complement Alternat Med. 2021 Nov 11;2021:1718709.|Evid Based Complement Alternat Med. 2022 Feb 15;2022:7889199.|Free Radic Biol Med. 2024 Aug 5:S0891-5849(24)00589-6.|Heliyon. 2024 Aug 22;10(17):e36664.|Int J Biol Macromol. 2024 Jul 26:134195.|Int J Mol Sci. 2023, 24(4), 3818.|J Clin Invest. 2024 Mar 7:e172716.|J Med Food. 2022 Jun 27.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Ovarian Res. 2024 Jan 15;17(1):18.|Life Sci. 2020 Aug 1;254:117590.|Mol Biol Cell. 2023 Mar 29;mbcE22110518.|Nat Commun. 2021 Jan 4;12(1):20.|Nat Commun. 2023 Apr 13;14(1):2109.|Oncol Res. 2024 May 23;32(6):1109-1118.|Open Life Sci. 2023, 18(1).|Phys Med Biol. 2020 Sep 24;65(19):195004.|Pulm Pharmacol Ther. 2023 Mar 9;102202.|Saudi J Biol Sci. 2023 Jun 15, 103707.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Research Square Preprint. 2023 Jul 10.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  50-18-0